<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400582</url>
  </required_header>
  <id_info>
    <org_study_id>MHI 06-890</org_study_id>
    <secondary_id>D2454L00003</secondary_id>
    <nct_id>NCT00400582</nct_id>
  </id_info>
  <brief_title>A Pharmacogenomic Study of Candesartan in Heart Failure</brief_title>
  <official_title>Effect of ACE Inhibitor Plus High Dose Candesartan on BNP and Inflammation in Patients With LV Dysfunction: Impact of Renin-angiotensin-aldosterone System Genetic Polymorphisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montreal Heart Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Montreal Heart Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of genetic variations on the response to
      candesartan in patients with heart failure who are already treated with an ACE inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BNP and NT-proBNP</measure>
    <time_frame>16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renin</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance/ glucose</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA functional class</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan up to 32 mg daily</intervention_name>
    <description>Candesartan 4 to 32 mg daily</description>
    <other_name>Atacand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Principal Inclusion Criteria:

          1. Male or female &gt; or = 18 years old.

          2. Symptomatic CHF corresponding to NYHA class II-IV symptoms for at least 4 weeks prior
             randomization.

          3. LVEF &lt; or = 40%

          4. Treatment with an optimal and stable dose of ACE inhibitor for at least 4 weeks prior
             to enrolment in the study.

        Principal Exclusion Criteria:

          1. Treatment with an ARB within 8 weeks prior to randomization.

          2. Known hypersensitivity to ARBs or ACE inhibitors.

          3. Creatinine clearance &lt; 30 ml/min or serum creatinine &gt; 221

          4. Current serum potassium &gt; or = 5.0 mmol/L or a history of marked ACE inhibitor or ARB
             induced hyperkalemia.

          5. Known bilateral renal artery stenosis.

          6. Current symptomatic hypotension and/or systolic B.P. &lt; 90 mmHg.

          7. Decompensated heart failure described as hospitalization or I.V. administration of
             medication in emergency room or heart failure clinic within 4 weeks

          8. Stroke, acute coronary syndrome, PCI within the last 4 weeks before randomization.

          9. Connective tissue disease or chronic inflammatory condition

         10. Acute inflammatory process such as an infection or gout attack in the last 2 weeks.

         11. Pregnant or lactating women or women of childbearing potential who are not protected
             from pregnancy by an accepted method of contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel White, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Simon de Denus, B. Pharm, MSc,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Heart Institute/ Faculty of Pharmacy, University of Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal Heart Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2006</study_first_submitted>
  <study_first_submitted_qc>November 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michel White</name_title>
    <organization>Montreal Heart Institute</organization>
  </responsible_party>
  <keyword>Heart failure</keyword>
  <keyword>Gene polymorphism</keyword>
  <keyword>Candesartan</keyword>
  <keyword>ACE inhibitors</keyword>
  <keyword>BNP</keyword>
  <keyword>Pharmacogenomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

